Lupus & antiphospholipid syndrome
Heart valve disease in primary antiphospholipid syndrome
Authors' conclusion
pAPS-HVD patients had a more severe APS clinical course including CAPS and thrombotic events as well as a specific serology, namely IgG isotype aPL antibodies and triple positivity.
Study context
- Population
- Patients with primary APS, with or without heart valve disease
- Participants
- 33 vs 128
- Exposure
- Primary APS (pAPS) with heart valve disease (HVD) vs pAPS with normal heart valves on echocardiography
- pAPS-HVDn = 33
- pAPS-controln = 128reference
- Outcome
- Clinical course and serology
Methodological detailsmulticentre
- Multicentre
Further findings
Cerebrovascular events
P = 0.005
Livedo reticularis
P = 0.013
CAPS
P = 0.034
Recurrent thrombosis
P < 0.001
Anti-β2-glycoprotein 1 IgG
P = 0.034
aCL IgG
P = 0.005
Triple positive aPL
P = 0.047
- Valve surgery (pAPS-HVD)
- 10 · events
Need for advanced therapy (IVIG, plasmapheresis or RTX)
- More frequent in pAPS-HVD
Valve surgery (pAPS-HVD)
- Associated with male gender, smoking, arterial limb ischaemia and livedo reticularis
Original publication
Heart valve disease in primary antiphospholipid syndrome. Rheumatology (Oxford). Published 12 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →